Progress in the development of preventive and therapeutic vaccines for hepatitis C virus

Journal of Hepatology

Volumn 54, Issue 6, 2011, Pages 1273-1285

  Torresi, Joseph ^a,b   Johnson, Doug ^a,b   Wedemeyer, Heiner ^c  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antivirals; Cellular immunity; Hepatitis C; Neutralising antibody; Preventative vaccines; Therapeutic vaccines; Vaccines

Indexed keywords

CHRONVAC C; EPITOPE; GI 5005; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE; IC 41; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NEUTRALIZING ANTIBODY; PEGINTERFERON; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT PROTEIN; RIBAVIRIN; TG 4040; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBODY RESPONSE; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIRUS ENTRY; VIRUS LIKE AGENT; VIRUS LOAD;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; EPITOPES; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; MODELS, IMMUNOLOGICAL; VIRAL HEPATITIS VACCINES; VIRUS INTERNALIZATION;

EID: 79956138217     PISSN: 01688278     EISSN: 01688278     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.09.040     Document Type: Review

References (160)

1. M.J. Alter Epidemiology of hepatitis C in the West Sem Liver Dis 15 1995 5 14
2. L. Alvarez-Lajonchere, N.H. Shoukry, B. Gra, Y. Amador-Canizares, F. Helle, and N. Bedard Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial J Viral Hepat 16 2009 156 167
3. L. Arribillaga, A.L. de Cerio, P. Sarobe, N. Casares, M. Gorraiz, and A. Vales Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus Vaccine 21 2002 202 210 (Pubitemid 35346815)
4. S. Auffermann-Gretzinger, E.B. Keeffe, and S. Levy Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection Blood 97 2001 3171 3176
5. C. Bain, A. Fatmi, F. Zoulim, J.P. Zarski, C. Trepo, and G. Inchauspe Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection Gastroenterology 120 2001 512 524 (Pubitemid 32147649)
6. E. Barnes, A. Folgori, S. Aston, K. Smith, A. Brown, and S. Capone Phase I trial of a highly immunogenic T-cell vaccine for hepatitis C virus based on novel adenoviral vectors from rare serotypes Hepatology 50 2009 A198
7. H. Barth, A. Ulsenheimer, G.R. Pape, H.M. Diepolder, M. Hoffman, and C. Neumann-Haefelin Uptake and presentation of hepatitis C virus-like particles by human dendritic cells Blood 105 2005 3605 3614 (Pubitemid 40628207)
8. B. Bartosch, J. Bukh, J.C. Meunier, C. Granier, R.E. Engle, and W.C. Blackwelder In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes Proc Natl Acad Sci USA 100 2003 14199 14204 (Pubitemid 37499214)
9. B. Bartosch, J. Dubuisson, and F.L. Cosset Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes J Exp Med 197 2003 633 642 (Pubitemid 36314658)
10. B. Bartosch, G. Verney, M. Dreux, P. Donot, Y. Morice, and F. Penin An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies J Virol 79 2005 8217 8229 (Pubitemid 40853525)
11. T.F. Baumert, S. Ito, D.T. Wong, and T.J. Liang Hepatitis C virus structural proteins assemble into virus like particles in insect cells J Virol 72 1998 3827 3836 (Pubitemid 28188682)
12. T.F. Baumert, J. Vergalla, J. Satoi, M. Thomson, M. Lechmann, and D. Herion Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate Gastroenterology 117 1999 1397 1407
13. M.B. Bernstein, M. Chakraborty, E.K. Wansley, Z. Guo, A. Franzusoff, and S. Mostbock Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells Vaccine 26 2008 509 521
14. M. Bharadwaj, D. Thammanichanond, C.K. Aitken, S. Moneer, H.E. Drummer, and S.L. Lilly TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus Immunol Cell Biol 87 2009 464 472
15. D.G. Bowen, and C.M. Walker Adaptive immune responses in acute and chronic hepatitis C virus infection Nature 436 2005 946 952 (Pubitemid 41191670)
16. + T cell immunity: HCV evolution, from chimpanzees to man J Exp Med 201 2005 1709 1714 (Pubitemid 41002889)
17. D.G. Bowen, and C.M. Walker The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? J Hepatol 42 2005 408 417 (Pubitemid 40254257)
18. A. Bowie, E. Kiss-Toth, J.A. Symons, G.L. Smith, S.K. Dower, and L.A. O'Neill A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling Proc Natl Acad Sci USA 97 2000 10162 10167
19. S. Capone, A. Meola, B.B. Ercole, A. Vitelli, M. Pezzanera, and L. Ruggeri A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques J Virol 80 2006 1688 1699 (Pubitemid 43228711)
20. A. Cerny, J.G. McHutchinson, C. Pasquinelli, M.E. Brown, M.A. Brothers, and B. Grabscheid Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif J Clin Invest 95 1995 521 530
21. K.-M. Chang, N.H. Gruener, S. Southwood, J. Sidney, G.R. Pape, and F.V. Chisari Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C J Immunol 162 1999 1156 1164 (Pubitemid 29035448)
22. Q.L. Choo, G. Kuo, R. Ralston, A. Weiner, D. Chien, and G. Van Nest Vaccination of chimpanzees against infection by the hepatitis C virus Proc Natl Acad Sci USA 91 1994 1294 1298 (Pubitemid 24058997)
23. B.Y. Chua, E.M. Eriksson, L.E. Brown, W. Zeng, E.J. Gowans, and J. Torresi A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection Vaccine 26 2008 4866 4875
24. S. Ciesek, H. Liermann, J. Hadem, T. Greten, H.L. Tillmann, and M. Cornberg Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection J Viral Hepat 15 2008 200 211 (Pubitemid 351143740)
25. Coates S, Choo Q-L, Kuo GC, Crawford K, Dong C, Wininger M, et al. Protection of chimpanzees against heterologous 1a viral challenge using a GEE1/GPE2 heterodimer vaccine. In: Jilbert AR, Grgacic EVL, Vickery K, Burrel CJ, Cossart YE, editors. 11th International symposium on viral hepatitis and liver disease; 2005; Sydney, Australia: Australian Center for Hepatitis Virology; 2005. p. 118-123.
26. J. Cohen The scientific challenge of hepatitis C virus Science 285 1999 26 30
27. P. Colombatto, M.R. Brunetto, A.M. Maina, V. Romagnoli, A. Craxi, and P. Almasio The candidate HCV E1E2MF59 vaccine is safe in chronic hepatitis C patients and accelerates the second phase viral decline upon primary response to pegylated interferon-2A/ribavirin therapy J Hepatol 50 2009 S22
28. S. Cooper, A.L. Erickson, E.J. Adams, J. Kansopon, A.J. Weiner, and D.Y. Chien Analysis of a successful immune response against hepatitis C virus Immunity 10 1999 439 449 (Pubitemid 29205480)
29. M. Cornberg, A.T. Chen, L.A. Wilkinson, M.A. Brehm, S.K. Kim, and C. Calcagno Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity J Clin Invest 116 2006 1443 1456
30. Dahari H, Feinstone S, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastrenterology 2010.
31. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection J Virol 71 1997 6011 6019 (Pubitemid 27304939)
32. + T cell responses using a HCV core ISCOMATRIXTM vaccine Human Vaccines 5 2009 151 157
33. M. Dreux, T. Pietschmann, C. Granier, C. Voisset, S. Ricard-Blum, and P.-E. Mangeot High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor B1 J Biol Chem 281 2006 18285 18295 (Pubitemid 44035485)
34. J. Dubuisson, F. Helle, and L. Cocquerel Early steps of the hepatitis C virus life cycle Cell Microbiol 10 2008 821 827 (Pubitemid 351386938)
35. G.A. Elmowalid, M. Qiao, S.-H. Jeong, B.B. Borg, T.F. Baumer, and R.K. Sapp Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees Proc Natl Acad Sci USA 104 2007 8427 8432 (Pubitemid 47175504)
36. M. Esumi, Y. Zhou, T. Tanoue, T. Tomoguri, and I. Hayasaka In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus Vaccine 20 2002 3095
37. P. Farci, H.J. Alter, D.C. Wong, R.H. Miller, S. Govindarajan, and R. Engle Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization Proc Natl Acad Sci USA 91 1994 7792 7796
38. P. Farci, A. Shimoda, D. Wong, T. Cabezon, D. De Gioannis, and A. Strazzera Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein Proc Natl Acad Sci USA 93 1996 15394 15399 (Pubitemid 27009611)
39. E. Fattori, I. Zampaglione, M. Arcuri, A. Meola, B.B. Ercole, and A. Cirillo Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes Gene Ther 13 2006 1088 1096
40. P. Feuerstadt, A.L. Bunim, H. Garcia, J.J. Karlitz, H. Massoumi, and A.J. Thosani Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients Hepatology 51 2010 1137 1143
41. C. Firbas, J. Bernd, E. Tauber, V. Buerger, S. Jelovcan, and K. Lingnau Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects Vaccine 24 2006 4343 4353
42. Firbas C, Boehm T, Buerger V, Schuller E, Sabarth N, Jilma B, et al. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine 2010.
43. A. Folgori, S. Capone, L. Ruggeri, A. Meola, E. Sporeno, and B.B. Ercole A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees Nat Med 12 2006 190 197 (Pubitemid 43214745)
44. A. Fournillier, E. Gerossier, A. Evlashev, D. Schmitt, B. Simon, and L. Chatel An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses Vaccine 25 2007 7339 7353 (Pubitemid 47484019)
45. A.J. Freeman, Y. Pan, C.E. Harvey, J.J. Post, M.G. Law, and P.A. White The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection J Hepatol 38 2003 349 356 (Pubitemid 36286549)
46. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
47. M. Gale Jr., and E.M. Foy Evasion of intracellular host defence by hepatitis C virus Nature 436 2005 939 945 (Pubitemid 41191669)
48. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
49. S. Giannini, E. Hanon, P. Moris, M. Van Mechelen, S. Morel, and F. Dessy Enhanced humoral and memory B cellular immunity using HPV16/18. L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only Vaccine 24 2006 5937 5949 (Pubitemid 44080367)
50. A. Grakoui, N.H. Shoukry, D.J. Woollard, J.H. Han, H.L. Hanson, and J. Ghrayeb HCV persistence and immune evasion in the absence of memory T cell help Science 302 2003 659 662 (Pubitemid 37310924)
51. J. Grebely, B. Conway, J.D. Raffa, C. Lai, M. Krajden, and M.W. Tyndall Hepatitis C virus reinfection in injection drug users Hepatology 44 2006 1139 1145 (Pubitemid 44748365)
52. J. Grebely, D.L. Thomas, and G.J. Dore HCV reinfection studies and the door to vaccine development J Hepatol 51 2009 628 631
53. L. Grollo, J. Torresi, H. Drummer, W. Zeng, N. Williamson, and D.C. Jackson Cross-reactive epitopes of hepatitis C virus induce antibodies that capture virions and inhibit pseudo virus particle cell entry Antiviral Therapy 11 2006 1005 1014
54. F. Habersetzer, T.F. Baumert, and F. Stoll-Keller GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection Curr Opin Mol Ther 11 2009 456 462
55. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
56. A.A. Haller, G.M. Lauer, T.H. King, C. Kemmler, V. Fiolkoski, and Y. Lu Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins Vaccine 25 2007 1452 1463 (Pubitemid 46074294)
57. F. Helle, and J. Dubuisson Hepatitis C virus entry into host cells Cell Mol Life Sci 65 2008 100 112 (Pubitemid 351152228)
58. F. Helle, A. Goffard, V. Morel, G. Duverlie, J. McKeating, and Z.Y. Keck The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein J Virol 81 2007 8101 8111 (Pubitemid 47101496)
59. G. Honnet, L. Veron, D. Olivier, B. Grellier, B. Marie-Bastien, and E. Bonfils Phase 1 clinical trial with a novel HCV therapeutic vaccine TG4040: interim results of biomarker and immunomonitoring analyzes Hepatology 50 2009 413A
60. M. Houghton Strategies and prospects for vaccination against the hepatitis C viruses Curr Top Microbiol Immunol 242 2000 327 339
61. M. Houghton, and S. Abrignani Prospects for a vaccine against the hepatitis C virus Nature 436 2005 961 966 (Pubitemid 41191672)
62. M. Hsu, J. Zhang, M. Flint, C. Logvinoff, C. Cheng-Mayer, and C.M. Rice Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles Proc Natl Acad Sci USA 100 2003 7271 7276 (Pubitemid 36706428)
63. I.M. Jacobson, J.G. McHutchison, T.D. Boyer, E.R. Schiff, G.T. Everson, and P.J. Pockros GI-5005 therapeutic vaccine plus PEG-IFN/ribavirin significantly improve virological response and ALT normalization at end-of-treatment and improves SVR24 compared to PEG-IFN/RIBAVIRIN in genotype 1 chronic HCV patients J Hepatol 52 2010 A2006
64. S.H. Jeong, M. Qiao, M. Nascimbeni, Z. Hu, B. Rehermann, and K. Murthy Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates J Virol 78 2004 6995 7003 (Pubitemid 38781538)
65. S.M. Kamal, K.N. Moustafa, J. Chen, J. Fehr, A. Abdel Moneim, and K.E. Khalifa Duration of peginterferon therapy in acute hepatitis C: a randomized trial Hepatology 43 2006 923 931 (Pubitemid 43724617)
66. T. Kanto, N. Hayashi, T. Takehara, T. Tatsumi, N. Kuzushita, and A. Ito Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals J Immunol 162 1999 5584 5591 (Pubitemid 29307172)
67. J.H. Kao, and D.S. Chen Global control of hepatitis B virus infection Lancet Infect Dis 2 2002 395 403
68. Z. Keck, A. Op De Beeck, K.G. Hadlock, J. Xia, T.-K. Li, and J. Dubuisson Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions J Virol 78 2004 9224 9232 (Pubitemid 39096532)
69. E. Khudyakov Yu, N.S. Khudyakova, D.L. Jue, S.B. Lambert, S. Fang, and H.A. Fields Linear B-cell epitopes of the NS3-NS4-NS5 proteins of the hepatitis C virus as modeled with synthetic peptides Virology 206 1995 666 672
70. C.S. Klade, A. von Gabain, and M. Manns Significant continuous viral load decline in treatment-naive HCV genotype 1patients after therapeutic peptide vaccination with IC41 Hepatology 50 2009 A1558
71. C.S. Klade, H. Wedemeyer, T. Berg, H. Hinrichsen, G. Cholewinska, and S. Zeuzem Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41 Gastrenterology 134 2008 1385 1395
72. C.S. Klade, H. Wedemeyer, T. Berg, H. Hinrichsen, G. Cholewinska, and S. Zeuzem Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41 Gastroenterology 134 2008 1385 1395
73. M. Kojima, T. Osuga, F. Tsuda, T. Tanaka, and H. Okamoto Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees Virology 204 1994 665 672 (Pubitemid 24330872)
74. M.J. Koziel, D. Dudley, N. Afdhal, A. Grakoui, C.M. Rice, and Q.L. Choo HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release J Clin Invest 96 1995 2311 2321
75. S.E. Krieger, M.B. Zeisel, C. Davis, C. Thumann, H.J. Harris, and E.K. Schnober Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations Hepatology 51 2010 1144 1157
76. A.D. Kwong, L. McNair, I. Jacobson, and S. George Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors Curr Opin Pharmacol 8 2008 522 531
77. V. Lamonaca, G. Missale, S. Urbani, M. Pilli, C. Boni, and C. Mori Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development Hepatology 30 1999 1088 1098 (Pubitemid 29458301)
78. B. Langhans, I. Braunschweiger, S. Schweitzer, G. Jung, G. Inchauspe, and T. Sauerbruch Lipidation of T helper sequences from hepatitis C virus core significantly enhances T-cell activity in vitro Immunology 102 2001 460 465 (Pubitemid 32322958)
79. M. Larsson, E. Babcock, A. Grakoui, N. Shoukry, G. Lauer, and C. Rice Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus J Virol 78 2004 6151 6161 (Pubitemid 38715913)
80. G.M. Lauer, E. Barnes, M. Lucas, J. Timm, K. Ouchi, and A.Y. Kim High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection Gastroenterology 127 2004 924 936 (Pubitemid 39208424)
81. + T-cell responses in acute hepatitis C virus infection and early therapy J Virol 79 2005 12979 12988 (Pubitemid 41433217)
82. G.M. Lauer, K. Ouchi, R.T. Chung, T.N. Nguyen, C.L. Day, and D.R. Purkis Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities J Virol 76 2002 6104 6113 (Pubitemid 34556305)
83. D. Lavillette, Y. Morice, G. Germanidis, P. Donot, A. Soulier, and E. Pagkalos Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection J Virol 79 2005 6023 6034 (Pubitemid 40617208)
84. M. Law, T. Maruyama, J. Lewis, E. Giang, A.W. Tarr, and Z. Stamataki Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge Nat Med 14 2008 25 27
85. E. Lawitz, I. Jacobson, J. McHutchinson, W. Lee, P. Pockros, and M. Shiffman GI-5005 Immunotherapy plus PEG-IFN/ribavirin versus PEG-IFN/ribavirin in genotype 1 chronic HCV subjects; preliminary phase 2 EVR analyses J Hepatology 50 2009 S230
86. M. Lechmann, K. Murata, J. Satoi, J. Vergalla, T.F. Baumert, and T.J. Liang Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice Hepatology 34 2001 417 423 (Pubitemid 32702356)
87. F. Lechner, D.K. Wong, P.R. Dunbar, R. Chapman, R.T. Chung, and P. Dohrenwend Analysis of successful immune responses in persons infected with hepatitis C virus J Exp Med 191 2000 1499 1512 (Pubitemid 30257347)
88. J.W. Lee, K. Kim, S.H. Jung, K.J. Lee, E.C. Choi, and Y.C. Sung Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies J Virol 73 1999 11 18 (Pubitemid 28565340)
89. W. Li, D.K. Krishnadas, J. Jie Li, D.L.J. Tyrrell, and B. Agrawal Induction of Primary Human T Cell Responses against hepatitis C virus-derived antigens NS3 or Core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy J Immunol 176 2006 6065 6075
90. + T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5 J Virol 82 2008 7492 7503 (Pubitemid 352031217)
91. M. Liu, H. Chen, F. Luo, P. Li, Q. Pan, and B. Xia Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses Vaccine 25 2007 6572 6580 (Pubitemid 47211519)
92. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
93. M. Matsui, O. Moriya, N. Abdel-Aziz, Y. Matsuura, T. Miyamura, and T. Akatsuka Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus Vaccine 21 2002 211 220 (Pubitemid 35346816)
94. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
95. J.G. McHutchison, I.M. Jacobson, T.D. Boyer, E.R. Schiff, G.T. Everson, and W.M. Lee GI-5005 therapeutic vaccine plus pegIFN/ ribavirin improves end of treatment response at 48 weeks versus pegIFN/ ribavirin in naive genotype 1 chronic HCV patients Hepatology 50 2009 229A
96. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
97. J.A. McKeating, L.Q. Zhang, C. Logvinoff, M. Flint, J. Zhang, and J. Yu Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner J Virol 78 2004 8496 8505 (Pubitemid 39025115)
98. I. Mederacke, H. Wedemeyer, and M.P. Manns Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection Curr Opin Investig Drugs 10 2009 181 189
99. P. Meuleman, J. Hesselgesser, M. Paulson, T. Vanwolleghem, I. Desombere, and H. Reiser Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo Hepatology 48 2008 1761 1768
100. J.C. Meunier, R.E. Engle, K. Faulk, M. Zhao, B. Bartosch, and H. Alter Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1 Proc Natl Acad Sci USA 102 2005 4560 4565 (Pubitemid 40397151)
101. J.C. Meunier, R.S. Russell, V. Goossens, S. Priem, H. Walter, and E. Depla Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus J Virol 82 2008 966 973
102. D. Meyer-Olson, N.H. Shoukry, K.W. Brady, H. Kim, D.P. Olson, and K. Hartman Limited T Cell Receptor Diversity of HCV-specific T Cell Responses Is Associated with CTL Escape J Exp Med 200 2004 307 319 (Pubitemid 39031250)
103. E. Meylan, J. Curran, K. Hofmann, D. Moradpour, M. Binder, and R. Bartenschlager Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus Nature 437 2005 1167 1172 (Pubitemid 41509355)
104. G. Missale, R. Bertoni, V. Lamonaca, A. Valli, M. Massari, and C. Mori Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response J Clin Invest 98 1996 706 714 (Pubitemid 26349175)
105. K. Murata, M. Lechmann, M. Qiao, T. Gunji, H.J. Alter, and T.J. Liang Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection Proc Natl Acad Sci USA 100 2003 6753 6758 (Pubitemid 36666652)
106. N. Nakamoto, D.E. Kaplan, J. Coleclough, Y. Li, M.E. Valiga, and M. Kaminski Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization Gastroenterology 134 2008 1927 1937 e1921-e1922
107. + T-cell epitope Hepatology 51 2010 54 62
108. C. Neumann-Haefelin, J. Timm, H.C. Spangenberg, N. Wischniowski, N. Nazarova, and N. Kersting Virological and immunological determinants of intrahepatic virus-specific CD8 T-cell failure in chronic hepatitis C virus infection Hepatology 47 2008 1824 1836 (Pubitemid 351945550)
109. F. Nevens, T. Roskams, H. Van Vlierberghe, Y. Horsmans, D. Sprengers, and A. Elewaut A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C Hepatology 38 2003 1289 1296 (Pubitemid 37314839)
110. B. Neveu, E. Debeaupuis, K. Echasserieau, B. le Moullac-Vaidye, M. Gassin, and L. Jegou Selection of High-Avidity CD8 T Cells Correlates with Control of Hepatitis C Virus Infection Hepatology 48 2008 713 722
111. C. Oseroff, A. Sette, P. Wentworth, E. Celis, A. Maewal, and C. Dahlberg Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses Vaccine 16 1998 823 833 (Pubitemid 28236652)
112. G. Papaevangelou, E. Dandolos, A. Roumeliotou-Karayannis, and S.C. Richardson Immunogenicity of recombinant hepatitis B vaccine Lancet 1 1985 455 456 (Pubitemid 15173154)
113. A. Penna, M. Pilli, A. Zerbini, A. Orlandini, S. Mezzadri, and L. Sacchelli Dysfunction and Functional Restoration of HCV-Specific CD8 Responses in Chronic Hepatitis C Virus Infection Hepatology 45 2008 588 601
114. J.M. Pestka, M.B. Zeisel, E. Blaser, P. Schurmann, B. Bartosch, and F.L. Cosset Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C Proc Natl Acad Sci USA 104 2007 6025 6030 (Pubitemid 47175652)
115. T. Pietschmann Virology: Final entry key for hepatitis C Nature 457 2009 797 798
116. T. Pietschmann, A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, and E. Steinmann Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras Proc Natl Acad Sci USA 103 2006 7408 7413 (Pubitemid 43727846)
117. A. Ploss, M.J. Evans, V.A. Gaysinskaya, M. Panis, H. You, and Y.P. de Jong Human occludin is a hepatitis C virus entry factor required for infection of mouse cells Nature 457 2009 882 886
118. N.K. Polakos, D. Drane, J. Cox, P. Ng, M.J. Selby, and D. Chien Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine J Immunol 166 2001 3589 3598 (Pubitemid 33117365)
119. + immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus Hepatology 44 2006 736 745 (Pubitemid 44433731)
120. H. Radziewicz, H.L. Hanson, R. Ahmed, and A. Grakoui Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections: potential for therapeutic application? Gastroenterology 134 2008 2168 2171 (Pubitemid 351783277)
121. + T Cells in Acute Infection Is Linked to Sufficient IL-2 Signaling J Immunol. 184 2010 2410 2422
122. A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. Di Iulio, and T. Mueller Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345 e1331-e1337
123. C.S. Rollier, G. Paranhos-Baccala, E.J. Verschoor, B.E. Verstrepen, J.A. Drexhage, and Z. Fagrouch Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity Hepatology 45 2007 602 613 (Pubitemid 46450611)
124. D. Rosa, S. Campagnoli, C. Moretto, E. Guenzi, L. Cousens, and M. Chin A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells Proc Natl Acad Sci USA 93 1996 1759 1763 (Pubitemid 26079830)
125. M. Sallberg, L. Frelin, H.M. Diepolder, M.-C. Jung, I. Mathiesen, and M. Fons A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C J Hepatol 50 2009 S18
126. P. Sarobe, J.J. Lasarte, N. Casares, A. Lopez-Diaz de Cerio, E. Baixeras, and P. Labarga Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins J Virol 76 2002 5062 5070 (Pubitemid 34441711)
127. P. Sarobe, D. Pendleston, T. Akatsuka, D. Lau, V.H. Engelhard, and S.M. Feinstone Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions J Clin Invest 102 1998 1239 1248 (Pubitemid 28436284)
128. E.R. Schiff, G.T. Everson, N. Tsai, N.H. Bzowej, R.G. Gish, and J.G.
129. + T cells - another important costimulatory molecule for the control of viral hepatitis Hepatology 50 2009 A1393
130. + Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes J Immunol 175 2005 3603 3613 (Pubitemid 41292019)
131. C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 2005 558 567 (Pubitemid 41196755)
132. S. Smyk-Pearson, I.A. Tester, D. Lezotte, A.W. Sasaki, D.M. Lewinsohn, and H.R. Rosen Differential antigenic hierarchy associated with spontaneous Recovery from hepatitis C virus infection: implications for vaccine design J Infect Dis 194 2006 454 463 (Pubitemid 44162656)
133. E. Spada, A. Mele, A. Berton, L. Ruggeri, L. Ferrigno, and A.R. Garbuglia Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance Gut 53 2004 1673 1681 (Pubitemid 39434114)
134. D. Steinmann, H. Barth, B. Gissler, P. Schurmann, M.I. Adah, and J.T. Gerlach Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C J Virol 78 2004 9030 9040 (Pubitemid 39096514)
135. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, and M.L. Abate IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
136. A.W. Tarr, A.M. Owsianka, J.M. Timms, P.C. McClure, R.J.P. Brown, and T.P. Hickling Characterization of the Hepatitis C Virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33 Hepatology 43 2006 592 601
137. D. Thammanichanond, S. Moneer, P. Yotnda, C. Aitken, L. Earnest-Silveira, and D. Jackson Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response Clin Immunol 128 2008 329 339
138. R. Thimme, D. Oldach, K.M. Chang, C. Steiger, S.C. Ray, and F.V. Chisari Determinants of viral clearance and persistence during acute hepatitis C virus infection J Exp Med 194 2001 1395 1406 (Pubitemid 33081515)
139. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, and C. O'Huigin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
140. A. Thompson, K. Patel, H. Tillman, and J.G. McHutchison Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges J Hepatol 50 2009 184 194
141. A.J. Thompson, and J.G. McHutchison Antiviral resistance and specifically targeted therapy for HCV (STAT-C) J Viral Hepat 16 2009 377 387
142. J. Torresi, M. Bharadwaj, D.C. Jackson, and E.J. Gowans Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy Curr Drug Targets 5 2004 41 56 (Pubitemid 38081741)
143. J. Torresi, A. Fischer, L. Grollo, W. Zeng, H. Drummer, and D.C. Jackson Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes Immunol Cell Biol 85 2007 169 173 (Pubitemid 46398722)
144. J. Torresi, O.M. Stock, A.E. Fischer, L. Grollo, H. Drummer, and I. Boo A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus Hepatology 45 2007 911 920 (Pubitemid 46631560)
145. S. Urbani, B. Amadei, E. Cariani, P. Fisicaro, A. Orlandini, and G. Missale The Impairment of CD8 Responses Limits the Selection of Escape Mutations in Acute Hepatitis C Virus Infection J Immunol 175 2005 7519 7529 (Pubitemid 41713450)
146. M. Vajdy, M. Selby, A. Medina-Selby, D. Coit, J. Hall, and L. Tandeske Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses J Gen Virol 87 2006 2253 2262 (Pubitemid 44178102)
147. T.J. van de Laar, R. Molenkamp, C. van den Berg, J. Schinkel, M.G. Beld, and M. Prins Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam J Hepatol 51 2009 667 674
148. C. Voisset, A. Op de Beeck, P. Horellou, M. Dreux, T. Gustot, and G. Duverlie High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry J Gen Virol 87 2006 2577 2581
149. + T cells in chronic hepatitis C virus infection J Immunol 169 2002 3447 3458 (Pubitemid 35013196)
150. H. Wedemeyer, W. Mazur, F. Nevens, Y. Horsmans, M. Adler, and H. Blum Factors influencing progression of liver fibrosis in patients with chronic hepatitis C: results of the 3-year T2S-918-HCV study with HCVE1 therapeutic vaccine J Hepatol 48 2008 S27
151. H. Wedemeyer, E. Schuller, V. Schlaphoff, R.E. Stauber, J. Wiegand, and I. Schiefke Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C Vaccine 27 2009 5142 5151
152. + T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection Hepatology 37 2003 577 589 (Pubitemid 36258780)
153. J. Wiegand, K. Deterding, M. Cornberg, and H. Wedemeyer Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha J Antimicrob Chemother 62 2008 860 865
154. D.K.H. Wong, D.D. Darryll, P.B. Bohrenwend, G.M. Lauer, R.T. Chung, and D.L. Thomas Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV J Virol 75 2001 1229 1235 (Pubitemid 32094682)
155. M. Yu, B. Bartosch, P. Zhang, Z.P. Guo, P.M. Renzi, and L. Shen Neutralising antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma Proc Natl Acad Sci USA 101 2004 7705 7710 (Pubitemid 38658093)
156. S. Yutani, N. Komatsu, S. Shichijo, K. Yoshida, H. Takedatsu, and M. Itou Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles Cancer Sci 100 2009 1935 1942
157. W. Zeng, S. Ghosh, Y.F. Lau, L.E. Brown, and D.C. Jackson Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines J Immunol 169 2002 4905 4912 (Pubitemid 35217155)
158. S. Zeuzem, T. Berg, B. Moeller, H. Hinrichsen, S. Mauss, and H. Wedemeyer Expert opinion on the treatment of patients with chronic hepatitis C J Viral Hepat 16 2009 75 90
159. P. Zhang, L. Zhong, E.B. Struble, H. Watanabe, A. Kachkob, and K. Mihalikb Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity Proc Natl Acad Sci USA 106 2009 7537 7541
160. A. Zibert, W. Kraas, H. Meisel, G. Jung, and M. Roggendorf Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus J Virol 71 1997 4123 4127 (Pubitemid 27172432)